Natus Medical Incorporated (NASDAQ:NTUS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Natus Medical Incorporated (NASDAQ:NTUS) have been given an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.

Zacks has also given Natus Medical an industry rank of 102 out of 255 based on the ratings given to related companies.

A number of brokerages have weighed in on NTUS. TheStreet raised shares of Natus Medical from a “d+” rating to a “c-” rating in a research note on Monday, September 30th. Zacks Investment Research downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 8th.

Shares of NASDAQ NTUS traded up $0.42 on Tuesday, reaching $34.10. 177,100 shares of the company’s stock traded hands, compared to its average volume of 140,789. Natus Medical has a 12 month low of $22.25 and a 12 month high of $34.89. The company has a 50 day moving average of $32.35. The stock has a market cap of $1.14 billion, a P/E ratio of 24.01 and a beta of 0.69. The company has a current ratio of 1.87, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12.

Natus Medical (NASDAQ:NTUS) last announced its earnings results on Thursday, October 24th. The company reported $0.36 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.02). Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.43%. The business had revenue of $123.46 million for the quarter, compared to the consensus estimate of $124.75 million. During the same period in the prior year, the business posted $0.40 EPS. Natus Medical’s revenue for the quarter was down 5.5% on a year-over-year basis. Analysts expect that Natus Medical will post 1.25 earnings per share for the current year.

In other Natus Medical news, CEO Jonathan Kennedy sold 6,684 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $31.54, for a total transaction of $210,813.36. Following the completion of the transaction, the chief executive officer now owns 148,441 shares of the company’s stock, valued at $4,681,829.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Dong Chune Christopher Chung sold 14,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $33.67, for a total transaction of $471,380.00. Insiders have sold 29,360 shares of company stock valued at $965,465 in the last ninety days. Insiders own 1.65% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: Liquidity

Get a free copy of the Zacks research report on Natus Medical (NTUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.